S. Wood

A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.

A. Armstrong, H. Hurwitz, D. George, 2014, Clinical genitourinary cancer.

Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.

M. Harrison, J. Moul, A. Armstrong, 2015, Clinical journal of oncology nursing.

Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma.

A. Clair, D. George, S. Wood, 2020, Future oncology.

Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.

C. Spritzer, A. Armstrong, J. Madden, 2020, Urologic oncology.

Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario

S. Roethke, S. Wood, J. C. Ryan, 2018, Journal of the Advanced Practitioner in Oncology.

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy

J. Moul, P. Tran, A. Armstrong, 2015, Prostate Cancer and Prostatic Disease.

Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario

S. Roethke, S. Wood, J. C. Ryan, 2018, Journal of the advanced practitioner in oncology.